Austin G Kulasekararaj
King's College Hospital NHS Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Austin G Kulasekararaj as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05116774 · BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyBioCryst Pharmaceuticals · terminated · Paroxysmal Nocturnal Hemoglobinuria (PNH) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:15 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.Blood · 2019317 citationsRCR 14.8
- Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.Haematologica · 2021109 citationsRCR 7.4
- 92 citationsRCR 9.7
- Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.Blood Adv · 201875 citationsRCR 3.2
- 73 citationsRCR 4.9
- Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.Eur J Haematol · 202265 citationsRCR 6.3
- 60 citationsRCR 3.1
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.Am J Hematol · 202453 citationsRCR 8.4
- 36 citationsRCR 2.2
- One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.Eur J Haematol · 202135 citationsRCR 2.3